Bristol-Myers, Osuka Get FDA OK for Abilify as Add-On Depression Treatment

Bristol-Myers Squibb Tuesday said it and partner Osuka Pharmaceutical Co. have received approval of a supplemental new drug application for the use of Abilify as an add-on treatment for depression from the Food and Drug Administration.
CNN Money